Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples
Detection Principle
ImmunoAssay-Antibody
Target
IgM and IgG
Testing Method Category
LFIA
Testing Method
Biolidics 2019-nCoV IgG/IgM Detection Kit lateral flow immunoassay
Testing Method - Additional Info
Validation of the lateral flow immunoassay (LFI) for rapid sxcreeninf and qualitative detection of anti-SARS-CoV2
Reported Performance
Specificity IgM: 92%; Specificity IgG: 100%; Specificity IgM and IgG: 92%; Day 0 Sensitivity IgM: 29%; D0 Sensitivity IgG: 21%; Day 0 Sensitivty IgM and IgG: 29%; Day7 Sensitivity IgM: 54%; D7 Sensitivity IgG: 88%; D7 Sensitivity IgM and IgG: 92% ; Plasma Sensitivity IgM: 59%; Plasma Sensitivity IgG: 86%; Plasma Sensitivity IgM and IgG: 95%; Whole Blood Sensitivity IgM: 55%; Whole Blood Sensitivity : 86%; Whole Blood Sensitivity IgM and IgG: 95%; Capillary Sensitivity IgM: 43%; Capillary Sensitivity IgG: 68%; Capillary Sensitivity Igm and IgG: 93%;
Sample Size
62 patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements